Craig Shadur
Nephrology · Des Moines, IANPI 1851354674
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $272,847 of the $314,156 with a category attached, or 86.9%. 17 manufacturers reported payments, led by AstraZeneca at 52.3% of the total. Reporting peaked in 2022 at $91,078 and has fallen 98.1% since, to $1,740 in 2025. Among nephrology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 407 payments — averaging $771.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$164K
- Bayer$107K
- Amgen$39K
- Otsuka America Pharmaceutical, Inc.$2K
- Sanofi-aventis U.S. LLC$351
- Calliditas Therapeutics US Inc.$251
- plus $871 from 11 others
Across 4 payments — averaging $11,233 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$33K
- GSK$12K
What the payments were for
- Consulting fees$2,8351%
- Speaking & faculty fees$272,84787%
- Travel & lodging$31,49410%
- Food & beverage$6,8612%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 224 | $164,158 |
| Bayer | 91 | $107,166 |
| Amgen(2 entities) | 68 | $39,094 |
| Otsuka America Pharmaceutical, Inc. | 3 | $2,265 |
| Sanofi-aventis U.S. LLC | 1 | $351 |
| Calliditas Therapeutics US Inc. | 2 | $251 |
| Mallinckrodt Enterprises LLC | 5 | $227 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $213 |
| Vertex | 1 | $210 |
| Vifor Pharma, Inc. | 2 | $44 |
| Travere Therapeutics, Inc. | 2 | $43 |
| GSK | 1 | $40 |
| Fresenius USA Marketing, Inc. | 2 | $33 |
| Amicus Therapeutics, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$314,156 in reported general payments places this provider in the 95th percentile of 73 nephrology providers in Iowa.
Other nephrology in Des Moines
- Prem ChandranDes Moines$19K
- Mark BelzDes Moines$2K
- Jobinson ThomasDes Moines$2K
- Arsalan AlviDes Moines$1K
- Robert SmithDes Moines$1K
- Sameer YaseenDes Moines$1K
- Jennifer ThompsonDes Moines$1K
- Dhivya SundaramurthyDes Moines$930
- Arani NanavatiDes Moines$930
- Bruce BuchsbaumDes Moines$702
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.